EnVivo Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
The executives of EnVivo Pharmaceuticals Inc. believe they've assembled a discovery platform that will identify good drug candidates for Alzheimer's disease (AD) and other neurological disorders. The start-up's plan hinges on the ability to insert human genes known to underlie AD into the fruit fly Drosophila, and to use these model organisms to screen for compounds that can ameliorate the condition. EnVivo has an automated way of monitoring flies that develop symptoms that management believes are pertinent to AD in humans.